UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012217
Receipt number R000014286
Scientific Title Exploratory randomized trial of evaluation for Tiotropium in lung cancer surgery
Date of disclosure of the study information 2013/11/05
Last modified on 2022/03/16 12:25:28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Exploratory randomized trial of evaluation for Tiotropium in lung cancer surgery

Acronym

Exploratory randomized trial of evaluation for Tiotropium in lung cancer surgery

Scientific Title

Exploratory randomized trial of evaluation for Tiotropium in lung cancer surgery

Scientific Title:Acronym

Exploratory randomized trial of evaluation for Tiotropium in lung cancer surgery

Region

Japan


Condition

Condition

Primary lung cancer

Classification by specialty

Chest surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

We will investigate the effect of Tiotropium on surgery for primary lung cancer exploratory in patients with Chronic Obstructive Lung Disease.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Rate of cardiopulmonary complications within 1 year after surgery

Key secondary outcomes

1)Improvement of pulmonary function before and after inhalation of Tiotropium
2)Rate of post operative complications excluding cardiopulmonary complications
3)3-years overall survival
4)Rate of adverse events
5)Evaluation of postoperative compliance


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification

NO

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Inhalation of Tiotropium, 5 microgram once daily, starting from 2 weeks before the surgery.

Interventions/Control_2

No inhalation of Tiotropium.
Other short acting anticholinergics or beta2-agonists are permissible.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Clinically suspected primary lung cancer.
2) Postbronchodilator FEV1/FVC (forced expiratory volume in 1s/forced vital capacity) < 0.70 assessed by spirometry.
3) Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria I - II (FEV1 => 50% of predicted value).
4) Modified Medical Research Council (MRC) score =< 1.
5) Resectable cancer lesion by surgery less than single lobectomy.
6) Without previously treatment for chronic obstructive pulmonary disease (COPD), bronchial
asthma.
7) No past pulmonary resection excluding wedge resection.
8) Patients stopping smoking at the time of giving the consent to this study.
9) Adequate organ function tolerable for the general anesthesia.
10) Capable of inhalation.
11) Age of 20 years or older.
12) ECOG (Eastern Cooperative Oncology Group) performance status (PS) 0-1.
13) Written informed consent to participate.

Key exclusion criteria

1) Median sternotomy.
2) Combined resection of the chest wall excluding parietal pleura excision.
3) History of active infection.
4) Active double cancer within 5 years of disease-free interval, except for curable lesions like
carcinoma in situ and mucosal cancer.
5) Patients with glaucoma.
6) Patients with dysuria.
7) History of hypersensitivity to atropine or drugs similar to atropine.
8) Patients with interstitial pneumonia or pulmonary fibrosis.
9) Patients with arrhythmia requiring antiarrhythmic continuously.
10) Patients with thyropathy.
11) Patients with renal dysfunction needs blood purification therapy.
12) Patients with psychiatric disease.
13) Patients requiring systemic steroids medication.
14) Patients with uncontrolled diabetes mellitus.
15) Patients with uncontrolled hypertension.
16) Current or previous within the last 6 months history of severe heart diseases, cerebrovascular
disease.
17) The pregnant and lactating female , female who has possibility of the pregnancy.
18) Patients who were judged inappropriate to entry this study by physician.

Target sample size

280


Research contact person

Name of lead principal investigator

1st name Masahiro
Middle name
Last name Tsuboi

Organization

National Cancer Center Hospital East

Division name

Thoracic Surgery

Zip code

277-8577

Address

6-5-1 Kashiwanoha, Kashiwa City, 277-8577, Japan

TEL

04-7133-1111

Email

mtsuboi@za2.so-net.ne.jp


Public contact

Name of contact person

1st name Teppei
Middle name
Last name Nishii

Organization

Yokohama City University Medical Center

Division name

Respiratory Disease Center

Zip code

232-0024

Address

4-57 Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan

TEL

045-261-5656

Homepage URL


Email

nteppei@yokohama-cu.ac.jp


Sponsor or person

Institute

Yokohama City University Medical Center

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Yokohama City University Ethics Committee

Address

3-9 Fukuura,Kanazawa-ku,Yokohama 236-0004 Japan

Tel

045-370-7629

Email

nextjim1@yokohama-cu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

横浜市立大学附属市民総合医療センター(神奈川県)
神奈川県立がんセンター(神奈川県)
順天堂大学医学部附属順天堂医院(東京都)
広島大学病院(広島県)
国立がん研究センター東病院(千葉県)
千葉県がんセンター(千葉県)
近畿大学医学部附属病院(大阪府)
東京医科大学病院(東京都)
聖マリアンナ医科大学病院(神奈川県)
産業医科大学病院(福岡県)
山口大学医学部附属病院(山口県)
新潟県立がんセンター新潟病院(新潟県)
倉敷中央病院(岡山県)
山形県立中央病院(山形県)
仙台厚生病院(宮城県)


Other administrative information

Date of disclosure of the study information

2013 Year 11 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

43

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2013 Year 03 Month 02 Day

Date of IRB

2013 Year 07 Month 25 Day

Anticipated trial start date

2013 Year 11 Month 05 Day

Last follow-up date

2020 Year 02 Month 29 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 11 Month 05 Day

Last modified on

2022 Year 03 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014286


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name